BMO Capital Upgrades Amgen to Outperform, Raises Price Target to $326
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman has upgraded Amgen (NASDAQ:AMGN) from Market Perform to Outperform and increased the price target from $286 to $326.

December 19, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's stock rating has been upgraded by BMO Capital from Market Perform to Outperform, with a price target increase from $286 to $326.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest a bullish outlook on the company's performance and potential. The increase in price target further reinforces the expectation of Amgen's stock price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100